Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLG-369
- Development stage
- Preclinical
- Lead developer
- University of Michigan
- Modality
- Small Molecules
01
Overview
DLG-369: sourced facts only. name: "We developed DLG-369, a potent inhibitor of the GAS41 YEATS domain with activity in NSCLC cellular models." [DOI:10.1158/1538-7445.am2024-3239]; target: "We developed DLG-369, a potent inhibitor of the GAS41 YEATS domain with activity in NSCLC cellular models." [DOI:10.1158/1538-7445.am2024-3239]; developer: "1University of Michigan, Ann Arbor, MI." [DOI:10.1158/1538-7445.am2024-3239]; modality: "We developed the first-in-class small-molecule inhibitors for the GAS41 YEATS domain." [DOI:10.1158/1538-7445.am2024-3239]; stage: "Furthermore, DLG-369 inhibits proliferation of NSCLC cell lines without affecting normal lung fibroblasts." [DOI:10.1158/1538-7445.am2024-3239]
02
Targets
YEATS1 (YEATS domain-containing protein 1)
Beyond the preview
Go deeper on DLG-369.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLG-369.